Juno Therapeutics Inc (JUNO.OQ)
16 Feb 2018
Fri, Feb 2 2018
* CELGENE CORPORATION COMMENCES TENDER OFFER FOR JUNO THERAPEUTICS, INC.
Celgene Corp said on Thursday that a pending $9 billion purchase of Juno Therapeutics in no way alters its focus on its partnership with Juno rival bluebird bio .
Jan 25 Celgene Corp said on Thursday that a pending $9 billion purchase of Juno Therapeutics in no way alters its focus on its partnership with Juno rival bluebird bio.
Celgene Corp will pay $9 billion in cash to buy experimental cancer drugmaker Juno Therapeutics Inc, bulking up its developmental pipeline as it works to reduce reliance on its own cancer treatment Revlimid. | Video
* Juno's CAR-T drug could rake in $3 bln worldwide in peak sales (Adds background and analyst quote, updates share price)
* Large drugmakers scour for products from smaller biotechs (Adds detail on gains in other biotech shares)
BRIEF-Juno Therapeutics Says If Deal Terminated By Co Or Celgene, Fee Of $300 Mln May Be Payable By Co To Celgene
* JUNO THERAPEUTICS SAYS IF DEAL TERMINATED BY CO OR CELGENE UPON SPECIFIED CONDITIONS, FEE OF $300 MILLION MAY BE PAYABLE BY CO TO CELGENE - SEC FILING
Jan 22 The following bids, mergers, acquisitions and disposals were reported by 1145 GMT on Monday:
Jan 22 Celgene Corp said on Monday it agreed to buy rest of Juno Therapeutics Inc for about $9 billion in cash to gain access to Juno's pipeline of CAR-T cancer drugs.
* CELGENE CORPORATION TO ACQUIRE JUNO THERAPEUTICS, INC., ADVANCING GLOBAL LEADERSHIP IN CELLULAR IMMUNOTHERAPY